Drug Discovery of Biologics Primer 201

Drug Discovery of Biologics Primer 201 builds upon the foundational knowledge of Drug Discovery of Biologics Primer 101, focusing on systematic insights into therapeutic antibody discovery. This course begins with the significance of antibody screening and structure-based affinity maturation, emphasizing antibody Chemistry, Manufacturing, and Controls (CMC) liabilities. Covering four therapeutic antibody classes, including immune checkpoint inhibitors, this class showcases the factors that influence early drug candidate selection. The data and transition criteria essential for advancing candidate drugs from the discovery phase to preclinical development are also covered. Enroll today to deepen your therapeutic antibody drug discovery knowledge!

Section 1: Drug Discovery Workflow

Explore the critical stages of drug development, from identifying and validating drug targets to selecting and optimizing lead candidates. Gain insights into preclinical and clinical development processes in the pharmaceutical industry.

Section 2: Affinity Maturation and CMC Liabilities

Dive into structure-based affinity maturation techniques, including targeted diversification, chain shuffling, and formulation. Understand the critical aspects of Chemistry, Manufacturing, and Controls (CMC) liabilities, covering issues like aggregation, solubility, immunogenicity, and glycation in drug development.

Section 3: Early Drug Candidate Selection

Explore the influence of drug size and complexity on target interactions, criteria in the drug discovery process, and the role of in silico, in vitro, and in vivo models. Delve into the functions and structures of human immunoglobulins, focusing on Fc and Fab regions.

Section 4: Antibody Diversity

Discover various therapeutic antibody classes, including canonical blocking antibodies, antibody-drug conjugates, antibody-like molecules, and immune response reactivators. Additionally, explore the essential concepts of cell banking, encompassing master cell banks and working cell banks.

Section 5: Discovery to Development Criteria

Explore the in vitro quantitative activity profile, covering in vitro ADME studies, pharmacokinetic studies, and pharmacokinetic biomarkers. Dive into in vivo efficacy studies, safety/toxicity studies, and learn how to estimate clinical doses and evaluate candidate transition criteria.

Five Takeaways


  1. Master the drug discovery workflow and align specific goals for successful development.
  2. Analyze the early drug candidate selection criteria and consider therapeutic antibody properties in the selection process.
  3. Utilize in silicon, in vitro, and in vivo models to investigate functional pharmacological activity.
  4. Demonstrate proficiency in the drug discovery considerations needed for the four distinct classes of antibody therapeutics.
  5. Investigate pharmacology data and transition criteria to determine which drug candidates are progressing into preclinical development.

Ready to get started?

Get in touch or enroll now

Powered By MemberPress WooCommerce Plus Integration